In early February 2026, the U.S. District Court for the District of Delaware denied Moderna’s bid for summary judgment in a ...

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

Researchers applied the Ribo-STAMP method to map protein translation in nearly 20,000 mouse hippocampal cells. The study ...

This study reports an important and novel finding that TENT5A, an enzyme involved in fine-tuning poly(A) tail length on selected mRNAs, is required for proper enamel mineralization in mice. The ...

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its ...

Researchers mapped nearly 91,000 healthy bone marrow cells from donors aged two to 32, creating the first pediatric atlas.

After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot ...

Moderna's application for its new flu vaccine has been accepted by the FDA following an initial rejection. This marks a notable shift in vaccine oversight during the Trump administration, raising ...

If you are wondering whether Moderna's current share price reflects its true potential, or if the market is still anchored to its pandemic story, this article will help you unpack what the numbers may ...

First mRNA vaccine to be produced in UK approved by regulators - The Moderna Innovation and Technology Centre will make millions of cutting-edge mRNA vaccines ...

A new case report was published in Volume 17 of Oncotarget on February 6, 2026, titled "Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of ...

Moderna received a refusal-to-file letter from the FDA objecting to how it conducted a 40,000-person trial comparing its new vaccine to a standard flu shot.